triazoles has been researched along with Anochlesia in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (66.67) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, N; Kumari, N; Luthra, PM; Mishra, CB; Mongre, R; Prakash, A | 1 |
| Borsini, F; Caprioli, A; Di Serio, S; Lombardo, K; Minetti, P; Pace, S; Riccioni, T; Stasi, MA; Vertechy, M | 1 |
| Bundgaard, C; Christoffersen, CT; Jørgensen, M; Rasmussen, LK; Redrobe, JP | 1 |
| Burdi, DF; Campbell, JE; Campbell, U; Engel, S; Hewitt, MC; Jones, PG; Lew, R; Quinton, MS | 1 |
| Grzelak, ME; Hodgson, RA; Hunter, JC; Parker, EM; Pond, AJ; Varty, GB | 1 |
| Arik, L; Bertorelli, R; Cohen-Williams, M; Foster, C; Fredduzzi, S; Greenlee, WJ; Hao, J; Lachowicz, J; Liu, H; Neustadt, BR; Ng, K; Stamford, AW; Varty, G; Zhang, H | 1 |
| Dziubina, A; Gołembiowska, K; Kamińska, K; Kowalska, M | 1 |
| Goode, T; Harris, A; Trevitt, J; Vallance, C | 1 |
| Ahmed, MA; Alkskas, IA; Azam, F; El-gnidi, BA | 1 |
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
| Barreiro, EJ; Dalla-Costa, T; Fenner, R; Fraga, CA; Heckler, AP; Menegatti, R; Neves, G; Rates, SM; Tasso, L; Viana, AF | 1 |
| Dziedzicka-Wasylewska, M; Pietraszek, M; Wardas, J | 1 |
| Chen, L; Engber, T; Grant, D; Hetu, G; Huang, C; Jin, X; Kumaravel, G; Peng, B; Petter, RC; Phadke, D; Reilly, J; Smits, G; Tam, S; Vu, CB; Zhang, J | 1 |
| Engber, T; Huang, C; Jin, X; Kumaravel, G; Pan, D; Peng, B; Petter, RC; Phadke, D; Reilly, J; Sha, L; Tam, S; Vu, CB | 1 |
| Bohnert, T; Chang, H; Engber, TM; Ensinger, CL; Huang, C; Kumaravel, G; Peng, H; Petter, RC; Sha, L; Van Vlijmen, H; Vu, CB; Wang, J; Whalley, ET; Yao, G | 1 |
| Chang, H; Conlon, PR; Engber, TM; Haque, S; Kiesman, WF; Kumaravel, G; Petter, RC; Sha, L; Wang, J; Whalley, ET; Yao, G | 1 |
| Engber, T; Grant, D; Hetu, G; Huang, C; Jin, X; Kumaravel, G; Pan, D; Peng, B; Petter, RC; Phadke, D; Reilly, J; Smits, G; Tam, S; Vu, CB | 1 |
| Caldwell, JP; Cohen-Williams, ME; Fawzi, A; Matasi, JJ; Tulshian, DB; Varty, GB; Zhang, H | 1 |
| Caldwell, JP; Cohen-Williams, ME; Fawzi, A; Higgins, GA; Matasi, JJ; Tulshian, DB; Varty, GB; Zhang, H | 1 |
| Borsini, F; Carminati, P; Di Cesare, MA; Ghirardi, O; Minetti, P; Stasi, MA; Varani, K; Vincenzi, F | 1 |
| Baldini, A; de Sanctis, AJ; Lisciani, R; Silvestrini, B | 1 |
21 other study(ies) available for triazoles and Anochlesia
| Article | Year |
|---|---|
8-(Furan-2-yl)-3-phenethylthiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione as novel, selective and potent adenosine A(2A) receptor antagonist.
Topics: Adenosine A2 Receptor Antagonists; Animals; Catalepsy; Cyclic AMP; HEK293 Cells; Heterocyclic Compounds, 3-Ring; Humans; Male; Mice; Molecular Docking Simulation; Motor Activity; Pyrimidines; Radioligand Assay; Receptor, Adenosine A2A; Rotarod Performance Test; Triazoles | 2014 |
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Basal Ganglia; Binding, Competitive; Catalepsy; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; HEK293 Cells; Humans; Injections, Intraperitoneal; Ligands; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Binding; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Transfection; Triazoles | 2015 |
Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Blood-Brain Barrier; Capillary Permeability; Catalepsy; Cognition; Cyclic Nucleotide Phosphodiesterases, Type 2; Exploratory Behavior; Humans; Male; Motor Activity; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Quinoxalines; Rats, Sprague-Dawley; Rats, Wistar; Recognition, Psychology; Triazoles | 2015 |
Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition.
Topics: Animals; Antipsychotic Agents; Benzimidazoles; Catalepsy; Cognition; Corpus Striatum; Cyclic GMP; Electroencephalography; Haloperidol; Humans; Male; Microdialysis; Motor Activity; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Sleep, REM; Triazoles | 2015 |
The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antipsychotic Agents; Caffeine; Catalepsy; Cebus; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Haloperidol; Neurologic Examination; Purines; Pyrimidines; Receptor, Adenosine A2A; Saimiri; Triazoles; Xanthines | 2008 |
Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Area Under Curve; Catalepsy; Chemistry, Pharmaceutical; Drug Design; Haloperidol; Models, Chemical; Parkinson Disease; Pyrimidines; Rats; Structure-Activity Relationship; Triazoles | 2009 |
Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Area Under Curve; Benserazide; Catalepsy; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Homovanillic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Rats; Rats, Wistar; Time Factors; Triazines; Triazoles; Xanthines | 2009 |
Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease.
Topics: Animals; Caffeine; Catalepsy; Dose-Response Relationship, Drug; Haloperidol; Male; Parkinson Disease; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Triazoles | 2009 |
Design, synthesis and anti-Parkinsonian evaluation of 3-alkyl/aryl-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thiones against neuroleptic-induced catalepsy and oxidative stress in mice.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Biomarkers; Brain; Catalepsy; Computational Biology; Drug Design; Furans; Glutathione; Lipid Peroxidation; Male; Mice; Molecular Structure; Neuroprotective Agents; Oxidative Stress; Oxidoreductases; Parkinson Disease; Pyrimidines; Specific Pathogen-Free Organisms; Thiones; Triazoles | 2010 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |
Dopaminergic profile of new heterocyclic N-phenylpiperazine derivatives.
Topics: Animals; Catalepsy; Dopamine Antagonists; Hypothermia; Male; Mice; Piperazines; Psychotropic Drugs; Pyrazoles; Rats; Rats, Wistar; Stereotyped Behavior; Structure-Activity Relationship; Time Factors; Triazoles | 2003 |
SCH 58261, a selective adenosine A2A receptor antagonist, decreases the haloperidol-enhanced proenkephalin mRNA expression in the rat striatum.
Topics: Analysis of Variance; Animals; Brain Mapping; Catalepsy; Corpus Striatum; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Enkephalins; Gene Expression Regulation; Haloperidol; In Situ Hybridization; Male; Nucleus Accumbens; Protein Precursors; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Wistar; Reaction Time; Receptor, Adenosine A2A; RNA, Messenger; Triazoles | 2003 |
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Biological Availability; Brain; Catalepsy; Heterocyclic Compounds, 2-Ring; In Vitro Techniques; Male; Mice; Parkinsonian Disorders; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Structure-Activity Relationship; Triazines; Triazoles | 2004 |
Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Catalepsy; Mice; Pyrimidines; Structure-Activity Relationship; Triazoles | 2004 |
Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Catalepsy; Disease Models, Animal; Drug Stability; In Vitro Techniques; Male; Mice; Microsomes, Liver; Molecular Structure; Parkinson Disease; Piperazines; Pyrimidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazines; Triazoles | 2004 |
Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Alkynes; Animals; Catalepsy; Cerebral Cortex; Disease Models, Animal; Mice; Oxidopamine; Parkinson Disease; Pyrazines; Rats; Structure-Activity Relationship; Triazoles | 2005 |
Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Binding, Competitive; Biological Availability; Catalepsy; Cerebral Cortex; Combinatorial Chemistry Techniques; Diamines; In Vitro Techniques; Male; Mice; Pyrrolidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Stereoisomerism; Triazines; Triazoles | 2005 |
2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Catalepsy; Disease Models, Animal; Drug Evaluation, Preclinical; Male; Molecular Structure; Pyrimidines; Rats; Structure-Activity Relationship; Triazoles | 2005 |
2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as adenosine A2A antagonists: the successful reduction of hERG activity. Part 2.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Catalepsy; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Molecular Structure; Motor Activity; Pyrimidines; Rats; Structure-Activity Relationship; Triazoles | 2005 |
ST 1535: a preferential A2A adenosine receptor antagonist.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Catalepsy; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dose-Response Relationship, Drug; Drug Interactions; Humans; Inhibitory Concentration 50; Male; Mice; Motor Activity; Radioligand Assay; Time Factors; Transfection; Triazoles; Tritium; Xanthines | 2006 |
Psychopharmacological profile of dapiprazole, a new potential antipsychotic agent.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Autonomic Nervous System; Behavior, Animal; Catalepsy; Conditioning, Operant; Female; Humans; Macaca mulatta; Male; Mice; Motor Activity; Pain; Piperazines; Rabbits; Rats; Social Isolation; Stereotyped Behavior; Substance Withdrawal Syndrome; Triazoles | 1982 |